1041852-85-0

Usage

Uses

Used in Pharmaceutical Industry:
4-[(2-fluoro-4-methylphenyl)amino]-6-[4-(2-hydroxyethyl)piperazin-1-yl]-7-methoxycinnoline-3-carboxamide is used as a potential drug candidate for its ability to interact with biological targets due to its unique structural features. The presence of the fluorine atom, methyl group, and 7-methoxy group may enhance its binding affinity and selectivity for specific receptors or enzymes, making it a promising candidate for the development of new therapeutic agents.
Further research is required to fully characterize the properties and potential uses of 4-[(2-fluoro-4-methylphenyl)amino]-6-[4-(2-hydroxyethyl)piperazin-1-yl]-7-methoxycinnoline-3-carboxamide, including its pharmacokinetics, pharmacodynamics, and safety profile. Once these aspects are better understood, it may find applications in various therapeutic areas, such as central nervous system disorders, cardiovascular diseases, or oncology, depending on its specific mechanism of action and efficacy in preclinical and clinical studies.

Upstream product

• 1041853-42-2 6-bromo-4-[(2-fluoro-4-methylphenyl)amino]-7-methoxycinnoline-3-carbonitrile 
• 1041853-91-1 4-(2-fluoro-4-methylphenylamino)-7-methioxy-6-(piperazin-1-yl)cinnoline-3-carbonitrile 
• 1041852-94-1 4-(2-fluoro-4-methylphenylamino)-7-methoxy-6-(piperazin-1-yl)cinnoline-3-carboxamide 

Relevant academic research and scientific papers

Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507

The potent and selective 3-amido-4-anilinoquinoline CSF-1R inhibitor AZ683 suffered from cardiovascular liabilities, which were linked to the off-target activities of the compound and ion channel activity in particular. Less basic and less lipophilic examples from both the quinoline and cinnoline series demonstrated cleaner secondary pharmacology profiles. Cinnoline 31 retained the required potency and oral PK profile, and was progressed through the safety screening cascade to be nominated into development as AZD7507.

CHEMICAL COMPOUNDS

The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-IR kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

3 - CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER

The invention relates to chemical compounds of formula (I): Formula (I), or pharmaceutically acceptable salts thereof which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti cancer effect in a warm blooded animal such as man.